CD34 and chronic myelogenous leukemia, BCR-ABL1 positive: To confirm this, we showed that DHODH inhibition in CML CD34+ cells increased ROS production and reduced mitochondria cell membrane potential after 3 days of Meds433 treatment (Fig. 5B).